Immunogenicity and Safety Study of GSK Biologicals' Trivalent Split Virion Influenza Vaccine Fluviral, Thimerosal-Free (FluLaval TF), in Adults 18 to 60 Years of Age.
Phase of Trial: Phase I
Latest Information Update: 09 May 2017
At a glance
- Drugs GSK 1536489A (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 04 Dec 2008 Status changed from active, no longer recruiting to completed.
- 30 Oct 2008 Planned end date changed to 1 Feb 2009 as reported by ClinicalTrials.gov.
- 30 Oct 2008 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.